Among the BPs, Targeting the NF-κB pathway has become an area of interest for potential therapeutic approaches in RCC, with the hope that inhibiting this pathway could reduce tumor progression and improve patient outcomes [128]. Here, NFKB1 is linked to renal cell carcinoma.